Breaking News: RayzeBio's RYZ101 became the first alpha-emitting radiopharmaceutical to deliver positive Phase 3 results, significantly improving progression-free survival in GEP-NET patients following Lu177 therapy.
Discover the scientific, clinical and commercial strategies that will become your blueprint for accelerating targeted radiopharmaceuticals from discovery to patients.
Showcase your technologies and services to 200+ senior decision-makers actively seeking CROs, CDMOs, isotope suppliers, radiopharmacies, dosimetry providers and specialist partners to advance the next generation of radiopharmaceuticals.
Be part of Europe's most comprehensive targeted radiopharmaceuticals forum, uniting pharma, biotech, regulators, clinical centres, investors and solution providers to shape the future of radioligand therapy.